Related Experiment Video

Updated: Mar 18, 2026

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice
08:32

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice

Published on: March 10, 2017

10.6K

[Fibroblast growth factor 23 in chronic kidney disease in children]

Magdalena Okarska-Napierała1, Piotr Skrzypczyk2, Małgorzata Pańczyk-Tomaszewska2

  • 1Medical University of Warsaw, Poland: Department of Pediatrics with Observational Ward.

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|July 13, 2016
PubMed

Insights

Fibroblast growth factor 23 (FGF23) may drive cardiovascular risk in children with chronic kidney disease (CKD). FGF23 impacts calcium-phosphorus metabolism and may directly harm heart muscle, necessitating further research.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Children with chronic kidney disease (CKD) face significantly elevated cardiovascular risk.
  • Fibroblast growth factor 23 (FGF23), discovered in 2000, is implicated in this risk.
  • FGF23 and α-Klotho protein regulate calcium-phosphorus metabolism, crucial in CKD.

Purpose of the Study:

  • To explore the role of FGF23 in cardiovascular complications in pediatric CKD.
  • To investigate FGF23's direct effects on cardiac health in children with CKD.
  • To assess FGF23's contribution to calcium-phosphorus imbalances in pediatric CKD.

Main Methods:

  • Review of recent clinical trials and studies in pediatric CKD populations.
  • Analysis of FGF23's interaction with its receptor on cardiomyocytes.
  • Examination of FGF23's impact on calcium-phosphorus metabolism and cardiovascular alterations.

Main Results:

  • FGF23 directly binds to cardiomyocyte receptors, promoting left ventricular hypertrophy.
  • Studies suggest FGF23 is key in developing calcium-phosphorus disturbances in pediatric CKD.
  • Evidence indicates FGF23's significance in cardiovascular damage pathogenesis in this group.

Conclusions:

  • FGF23 plays a critical role in cardiovascular risk and damage in children with CKD.
  • Further large-scale clinical trials are needed to confirm FGF23's role.
  • Understanding FGF23's mechanisms may lead to novel therapeutic strategies for pediatric CKD patients.

Keywords:
cardiovascular riskchildrenchronic kidney diseasefibroblast growth factor 23

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.3K
Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
581
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
290
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
890
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
971
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate01:25

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...
88
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.2K